---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-051573"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:44:00.600901+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Q1 rev $211M, net loss narrows; secures $1.5B; launches BBOT

## Summary
- Revenue $211.1M vs $1.8M YoY; net loss $35.2M vs $140.2M prior year.
- Launched BBOT oncology subsidiary with $200M private financing led by Cormorant and Omega.
- Secured up to $1.5B via Bayer licensing (up to $310M milestones), royalty financing, and equity.
- Acoramidis NDA PDUFA date Nov 29, 2024; EMA MAA accepted, expected approval 2025.
- Ended Q1 with $519.8M cash; cash position strengthened significantly.

## SEC filing metadata
- accession: 0000950170-24-051573
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000095017024051573/0000950170-24-051573-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000095017024051573/bbio-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-051573
- JSON: https://secwatch.observer/filing/0000950170-24-051573.json
- Plain text: https://secwatch.observer/filing/0000950170-24-051573.txt

## Key facts
- Earnings Releases
  BridgeBio Pharma, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: BridgeBio Pharma, Inc. reported recent business updates and its financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000095017024051573/0000950170-24-051573-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.